RAPT director awarded 4,956 RSUs
RAPT Therapeutics reported an equity grant to director Scott Braunstein.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RAPT Therapeutics reported an equity grant to director Scott Braunstein. On 01/30/2026, he received 4,956 shares of common stock at a price of $0 per share as a stock-based award, leaving him with 4,956 shares beneficially owned directly.
The award represents the annual grant of restricted stock units (RSUs) under RAPT’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 4,956 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did RAPT (RAPT) report for Scott Braunstein?
What is the vesting schedule for Scott Braunstein’s RSUs at RAPT (RAPT)?
What policy governs Scott Braunstein’s stock grant at RAPT (RAPT)?
AI-generated analysis. How Rhea-AI works. Not financial advice.